Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Message to whoever has been buying the dips for the last couple of weeks, slowly raising the share price.
KEEP DOING THAT.
Thank You
Hello, triple digits may be hard, if everything goes perfect for a few more years, then maybe, sorry, just trying to be somewhat rational.
Great news might bring $20+ in a short time , above $50 would need a TON of revenue I would think.
Now, can we keep climbing? Hope so.
ARE WE ALL RICH YET?
Phantom, Thank You for contacting JV and filling us in. Your timeline for event seems the most reasonable.
I think our main problem is, Nobody has heard of MRKR, Doctors, Patients, Investors.
I have not and will not sell a single share, but I kind of give up trying to figure this price.
3 patients, 2 great news and 1 good news, AND IT DOES BASICALLY NOTHING ???
Have a great summer.
Thank You
I think so but not positive. It may just be a rehash of what they just gave us.
Cash looks OK also:
Cash Position and Guidance: At March 31, 2024, Marker had cash and cash equivalents of $11.3 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025, inclusive of available drawdowns from grant funds.
It all sounds good so far, 3 patients, 3 for 3 good results.
First study participant treated with MT-601 had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including a relapse within 90 days of anti-CD19 CAR T cell therapy (Breyanzi) (PRESS RELEASE, JUNE 12, 2023). Without prior lymphodepletion, this participant achieved a complete response eight weeks after the second infusion of MT-601 and remains in complete response nine months after initial treatment with MT-601 (PRESS RELEASE, APRIL 8, 2024).
Another study participant had transformed follicular Non-Hodgkin’s Lymphoma (NHL) and failed 12 lines of therapy, including bispecific T cell engager therapy (mosunetuzumab) for follicular NHL, and anti-CD19 CAR T cells (Yescarta) after transformation into DLBCL. At the time of MT-601 infusion, only follicular NHL persisted in this patient. Eight weeks after initial infusion with MT-601 without prior lymphodepletion, the study participant achieved a complete response, which remains three months following treatment with MT-601(PRESS RELEASE, APRIL 8, 2024).
The third study participant treated had DLBCL with cutaneous involvement and was not eligible for CAR T cell therapy. This participant achieved a partial response eight weeks after MT-601 treatment without prior lymphodepletion with all lesions decreasing in size including one that has completely resolved (PRESS RELEASE, APRIL 8, 2024).
Treatment was well tolerated among all patients with no significant treatment-related adverse events including cytokine release syndrome or neurotoxicity.
Thank You. sounds good ... for now.
Thank You. Hope something comes out of MT-401 OTS.
I'm guessing that this no new nothing news means that there ain't going to be any earth shattering news given by Juan at tomorrows presentation.
YAWN!
Ho Hum, it looks like the same Old information being told again for the 10th time.
Thanks for the update on lymphoma patient #1 again, again.
MARKER THERAPEUTICS REPORTS YEAR-END 2023 CORPORATE AND FINANCIAL RESULTS
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-year-end-2023-corporate-and
Hello Phantom, asking in advance. After Juan does his March 26 presentation, can you translate it here and give your outlook? Thank You
volume 17,000 , that's not a lot of excitment.
Nice move, but the pitiful volume Sucks.
Ho Hum. go mrkr. rah rah rah.
should start tomorrow.
Lymphoma patient #2? Lymphoma patient #3? We can expect some data when?
Well, we can look at the bright side. At least we have the name "Neldaleucel" ready ... in case we ever get to use it to market ...
in 3 or 4 years if we're lucky.
GO METS you see we have out own "Acuna" now.
OK, let me get this straight.
It has been more than 20 years since TPIV came public,
about 6 years since the MRKR merger,
and what we have to show for it is basically nothing.
All TPIV legacy gone bye bye.
MRKR AML just about gone bye bye.
And here we are, back to almost square one, with a single early Phase 1 Lymphoma trial.
Just Peachy.
Marker Therapeutics, Inc. has terminated its stock sale agreement with Lincoln Park Capital Fund, effective March 1, 2024, citing sufficient financial runway until the fourth quarter of 2025, negating the immediate need for further capital.
Well, at least we were given information on the first lymphoma study participant for what, the FOURTH or FIFTH TIME now.
Thank You for the helpful update.
Do I detect a wee bit of sarcasm?
If so, I 100% agree with it.
Thank You, I guess that news is better than a sharp stick in the eye.
Now just let it lead to something meaningful and profitable.
If in March we get the FDA hold lifted ... and let's say that pushes the price past $20, which I think is more than reasonable, with just the rest of their pipeline which is using the Same therapy that is already proven and approved, that should be worth what? Somewhere between $30 and $40.
So seriously, IF BEFORE we even factor in ever increasing revenues that will be coming in, any buy out offer would have to be north of $50, perhaps well north.
4AM BLAST OFF 🚀🚀🚀💲💲💲👀💲💲💲🚀🚀🚀😵
A MRKR cancer competitor (but not much) IOVA got an early FDA approval today, good box label, (posted here 2 days ago and before).
P.S. - after almost 7 decades, you taught me something,
I never knew the word was drivel or seen it spelled out.
I always thought it was dribble. Thanks
P.P.S. I miss all them potato fields and chicken farms from our youth on L.I. (and everything that went with them),
with all of our modern technology, it seems like this world just gets worse and worse, I liked it better when neighbors and people actually cared about each other, and we were allowed to have freedom of speech and our own opinions without cancel culture.
Howdy ATL. GO MRKR - GO METS
I haven't seen any of his posts because I have barchild blocked, but I'm guessing that he is still babbling on with his assinine dribble.
MRKR just kind of hanging out here.
10 days left before IOVA date for FDA PDUFA approval.
New T cell therapy for Lymphoma ... clinical trials still a few years away.
https://www.msn.com/en-us/health/other/new-technique-could-make-human-t-cells-100-times-more-potent-at-killing-cancer-cells/ar-BB1hVKbW?ocid=msedgdhp&pc=U531&cvid=7a02c55157864e2ba3eef48328824d64&ei=17
"a gene fusion, CARD11–PIK3R3, found in a CD4 cutaneous T cell lymphoma, that augments CARD11–BCL10–MALT1 complex signalling and anti-tumour efficacy of therapeutic T cells in several immunotherapy-refractory models in an antigen-dependent manner."
https://www.nature.com/articles/s41586-024-07018-7
Good Luck to both of us.
No, it did not. I am a long term investor in this, I still have faith for much bigger things in the future.